Edition:
United States

Genetic Technologies Ltd (GENE.OQ)

GENE.OQ on NASDAQ Stock Exchange Capital Market

1.30USD
2 Dec 2016
Change (% chg)

$-0.10 (-7.14%)
Prev Close
$1.40
Open
$1.40
Day's High
$1.40
Day's Low
$1.23
Volume
237,927
Avg. Vol
66,576
52-wk High
$3.47
52-wk Low
$1.20

GENE.OQ

Chart for GENE.OQ

About

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment... (more)
No analyst recommendations are available for GENE.OQ.

Overall

Beta: 1.08
Market Cap(Mil.): $15.16
Shares Outstanding(Mil.): 11.44
Dividend: --
Yield (%): --

Financials

  GENE.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.54 -- --
ROI: -54.68 -1.09 14.95
ROE: -54.85 -2.39 16.29

BRIEF-Genetic Technologies and the University of Melbourne enter into worldwide license agreement to develop colorectal cancer risk assessment test

* Genetic Technologies Limited and the University of Melbourne enter into exclusive worldwide license agreement to develop colorectal cancer risk assessment test Source text for Eikon: Further company coverage:

Nov 29 2016

BRIEF-Genetic Technologies entered into license agreement with University Of Melbourne

* Asx alert-license agreement to develop colorectal cancer risk test-GTG.AX

Nov 28 2016

Competitors

  Price Chg
Sonic Healthcare Limited (SHL.AX) $21.65 -0.30
Healthscope Ltd (HSO.AX) $2.23 -0.03

Earnings vs. Estimates